Article info
PDFHemorrhagic Stroke
Original research
Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience
- Correspondence to Professor Ahmed Elbassiouny, Department of Neurology, Ain Shams University Faculty of Medicine, Cairo 11566, Egypt; ahmedelbassiony{at}gmail.com
Citation
Safety and efficacy of ticagrelor as single antiplatelet therapy in prevention of thromboembolic complications associated with the Pipeline Embolization Device (PED): multicenter experience
Publication history
- Received March 1, 2020
- Revised April 8, 2020
- Accepted April 10, 2020
- First published May 29, 2020.
Online issue publication
January 08, 2022
Article Versions
- Previous version (15 October 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.